Role of ALBI Score and Sarcopenia As Prognostic Predictors Among Hospitalized Cirrhotic Patients with Hepatic Encephalopathy

NCT06679868 | Not Yet Recruiting

• 1 other identifier: ALBI and Sarcopenia in LC
• Study Type: observational
• Target: 106
• Locations: 0 countries
• Sites: N/A

Brief Summary

To evaluate the role of ALBI score in predicting prognosis and hospital mortality of hospitalized cirrhotic patients with hepatic encephalopathy. To verify the best scoring system for predicting prognosis and survival among those patients. To investigate whether the presence of sarcopenia could add to the prognostic role of ALBI score.

Conditions

Liver Cirrhosis

Outcome Measures

Primary Outcomes (1)

• 1- Evaluation of the role of ALBI score in predicting prognosis and hospital mortality of hospitalized cirrhotic patients with hepatic encephalopathy. 2- Verification of the best scoring system for predicting prognosis and survival among those patients

  ALBI score can be assessed by following formula : 0.66Xlog(bilirubin.mg/dl)\_0.085X(albumin.g/dl)The cut-off points for ALBI grades are:Grade I : less than -2.60(lowest mortality risk)Grade II : -2.60 to - 1.39(Intermediate)Grade III : more than -1.39 (Highest ) Follow up of those patients and record of improvement, deterioration or death will be done.

  ALBI score/at admission and follow up of patients /after 1 month

Eligibility Criteria

• Age: 20 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Prospective

You may qualify if:

• All cirrhotic patients with hepatic encephalopathy admitted to Al-Rajhi liver hospital.

You may not qualify if:

• Patients with acute hepatic failure and those with previous portosystemic surgery or TIPS.
• Patients with prior liver or other organs transplantation.
• End stage renal disease(ESRD), and HCC or other solid tumors.
• Patients on marivan for any cause.
• Patients with extra-hepatic biliary obstruction.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (2)

• Chen H, Yang C, Yan S, Liu X, Zhou L, Yuan X. Sarcopenia in cirrhosis: From pathophysiology to interventional therapy. Exp Gerontol. 2024 Oct 15;196:112571. doi: 10.1016/j.exger.2024.112571. Epub 2024 Sep 9.

  PMID: 39236869 BACKGROUND

• Hsieh YC, Lee KC, Wang YW, Yang YY, Hou MC, Huo TI, Lin HC. Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score. PLoS One. 2018 Dec 12;13(12):e0208903. doi: 10.1371/journal.pone.0208903. eCollection 2018.

  PMID: 30540824 BACKGROUND

MeSH Terms

Conditions

Liver Cirrhosis

Condition Hierarchy (Ancestors)

Liver Diseases; Digestive System Diseases; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Heba Saad Abu Elsoud, Resident Doctor

CONTACT

00201064375775; hsaad7355@gmail.com

Hanan Mohammed Nafeh, Professor

CONTACT

00201003053369; hmnafeh@yahoo.Com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: HSAAD

Study Record Dates

• First Submitted: September 6, 2024
• First Posted: November 8, 2024
• Study Start: November 1, 2024
• Primary Completion: October 1, 2025
• Study Completion: November 1, 2025
• Last Updated: November 8, 2024

Record last verified: 2024-11